Member Info for draft

Cell Culture Flow Systems Quasi Vivo Systems are a series of advanced, interconnected cell culture flow systems, specifically designed to improve cellular phenotypes and human in vivo relevance of in vitro cell culture models. By introducing flow to the in vitro environment, Quasi Vivo enables you to generate models with improved predictive value, greatly improving confidence in the validity of your results. The system consists of interconnected cell culture chambers and a peristaltic pump to create a continuous flow of media over cells. It is available with three different culture chambers (QV500, QV600, and QV900) to support a wide range of applications, including submerged cell culture, coculture, and modeling of air�liquid and liquid�liquid interfaces. Not only is the system easy to set up, it also enables close monitoring of variables during an experiment. Furthermore, its large scale and user configurability allow researchers to perform assays that are not possible with microfluidic systems. Lonza

I think it is safe to assume Trevor will keep costs really low. And sales channels we have are: GE healthcare India China US hospital already using Imaging Biometrics Latest hospitals using Feedback PACS software the fact UK hospitals are using Feedback PACS means we will easily get Stone Checker in there as it is PACS compliant.

http://www.healthcareitnews.com/news/fda-chief-sees-big-things-ai-healthcare At AcademyHealth�s 2018 Health Datapalooza on Thursday, the U.S. Food and Drug Administration offered a vote of confidence for artificial intelligence in healthcare, promising more refined strategies for regulation, touting its tech incubator for AI innovation and announcing a new machine learning partnership with Harvard. "We�re implementing a new approach to the review of artificial intelligence," said FDA Commissioner Scott Gottlieb, MD. As one example, he pointed to the agency's approval earlier this year of a new clinical decision support software that uses AI algorithms to help alert neurovascular specialists of brain deterioration faster than existing technologies. "AI holds enormous promise for the future of medicine, and we�re actively developing a new regulatory framework to promote innovation in this space and support the use of AI-based technologies," said Gottlieb. "So, as we apply our Pre-Cert program � where we focus on a firm�s underlying quality � we�ll account for one of the greatest benefits of machine learning � that it can continue to learn and improve as it is used." Doing so, he said, "may allow a firm to make certain minor changes to its devices without having to make submissions each time." FDA also plans to ensure its regulatory framework and software validation tools are "sufficiently flexible to keep pace with the unique attributes of this rapidly advancing field," said Gottlieb. That said, the agency still needs to "establish appropriate guardrails for patients," he emphasized. "And even as we cross-new frontiers in innovation, we must make sure that these novel technologies can deliver benefits to patients by meeting our standards for safety and effectiveness. The technology won�t be scaled or reimbursed without that level of confidence that it protects and promotes patients." Gottlieb said the agency is fully expecting to see an ever-increasing number of AI-powered healthcare tools submitted for approval in the years to come, from imaging devices to technology derived from other industries such as finance "that are already widely using AI platforms for fraud detection." FDA's regulatory approach will "focus on the ways in which real-world data flows," he said. "This includes structured and unstructured data from pathology slides, electronic medical records, wearable devices, and insurance claims data. We want to better understand, and unlock ways, that this data can be used to inform development and validation of AI devices." Whether tools that can scan digital biomarkers for early diagnosis, or leverage EHRs to enable clinical trials at the point of care � or even technology that someday "might even be taught to explain itself to clinicians � Gott

Lithotripters can cost from $100,000 to $200,000 - so easier to just sell this software as part of a lithotripsy equipment,

and what about the training, Urologists will need to be trained on interpreting the software surely?

feedback has sales, this company will also have sales. Its just piggy backing the contacts from there so hope we get some fast sales growth.

upfront cost of purchasing the StoneChecker software so that it can accessed locally an unlimited number of times is expected to be �15,000 with annual recurring revenues based on software maintenance and upgrades, which may include improvements to the TexRAD algorithm based on additional patient data. The intention is to charge a maintenance fee of between �1,500 and �2,000 per year depending on the updates offered. If no additional updates are offered then the maintenance fee may be lowered. Okay so to hit �1million revenue they need to sell 77 software packs. 77 * �15,000. Where can they do this? US, UK, China, Germany , India. Problem is not everyones going to be willing to fork out �15,000 and a lot of urology clinics tend to be private clinics. To elabroate Urology clinics tend to be small and independent, I think they might some sales very quickly - like maybe 10 just from existing contacts and networks but 77 is a big target. Of course the surprising factor could be a NHS deal or private Urology practice deals. How many Urology clincs in NHS UK? Difficult to get exact number if hospital in UK as managed under Trusts, There are 168 trusts. Id knock 30 off just for dirty calculation figure, knock another 30 off as never approached by the sales team here. Pure fag packet calc. so 100 hospitals - so maybe FBDU can pick up a mill here The good thing is there will be recurring revenue from updates and maintenance. It looks like the bigger opportunity will come from direct selling with the Lithotripter manufacturers,

go read the ************* article

go read the ************* article

One market leader in the manufacture and sale of lithotripsy solutions has expressed a high level of interest in the StoneChecker product subject to due diligence when the commercial product is available following completion of the patient studies.

Took a few off as precaution.

later on.

Just needs same annoucment as Feedback and this will go flying. GE in India must be the India deal they are looking at , these guys are using their feedback and Imaging Biometrics contacts

by FB. we really should be higher than this, the RNS was late in the day - doesnt help at all. The name of the company doesnt represent imaging at all. Its RNS could be getting missed by aim punters as this is main market. Just going to have to hold. If wider marker picks up on this can easily get to 20p plus. in my opinion. No advice intended.

- Create a new company to support product maintenance and development, regulatory clearances, commercialisation including international sales channel management - Recruit a high quality hands-on Chief Operations Officer to further refine the business plan, drive commercial sales and oversee recruitment. In particular, the COO will be responsible for increasing sales of Imaging Biometrics' products in the US and launching these products in India, China and Europe (Q3 2018) - Recruit one administrative support worker and marketing staff (Q4 2018) - Obtain FDA clearance for StoneChecker Software (Q2/Q3 2018) and then market StoneChecker Software commercially in the US, India and China (completion: Q3/Q4 2018) - Appoint a second person to the Business Development team to be responsible for the US and other North American markets. - Design and manufacture a commercial version of the cloud-based interface for StoneChecker Software (completion: Q3 2018) - Commercial sales of StoneChecker Software in the UK (completion: Q4 2018) - Create a network of distributors worldwide (Ongoing) - Setting up reference centres across important research centres in association with key opinion leaders; - Setting up a clinical case registry to collect anonymised case data, to be used to develop Artificially Intelligent products at a future date; - Supporting the conduct of investigator led studies at renowned academic institutions globally; - Setting up cloud services platform and innovative licensing models (e.g. subscription-model, pay per use etc and having the necessary infrastructure and payment portal, tracking customer usage) for the Products; - Developing next generation/improved versions of StoneChecker Software and Imaging Biometrics' products; - Applying for and maintaining regulatory clearances with the appropriate national competent authorities.

I took a few last week - im 15% up now. If governments regulate crypto this is going to go flying back up

You are right - extremely Bullish, even mentioned JOG and statoil - if China comes in WOW - we are going to be MINTED

This was also in Fridays Evening standard on the tube. This is the best level to buy and accumulate. And then hold for the 50p plus in 2-3 years time i reckon in my opinion, no advice intended. I will be holding these for dear life. multi-millionaire who pours cash into the coffers of the Conservative Party is now the largest single shareholder in North Sea oil and gas firm Cluff Natural Resources.Entrepreneur and philanthropist Michael Spencer owns about 9% of the company after snapping up more than 40million shares, increasing his interest from 6.31%. Investment manager Hargreaves Lansdown has a slightly larger shareholding but its stake is held on behalf of �nominees�. Mr Spencer, once dubbed the city�s richest man, has acquired his shares in Cluff through an investment company he controls, IPGL.He previously founded interdealer broker Icap, which in 2010 issued a shock profits warning just weeks after he sold a large stake for �45 million.Icap, which was fined in both the UK and US for its part in the global Libor interest rate scandal, became fintech company Nex Group in late 2016 after part of the business was sold to global banking firm Tullett Prebon.Mr Spencer is now chief executive of Nex Group and also chairman of the Conservative Foundation, a charity launched in 2009 to raise money for the Tories. He was Conservative Party treasurer from 2006 to 2010, helping to turn a funding deficit into a surplus, and has pumped millions of pounds into the party both personally and through his businesses. Close friend and former prime minister David Cameron recommended him for a peerage but the move was reportedly scuppered by the Libor scandal.Mr Spencer, EY�s world entrepreneur of the year in 2010, has helped raise tens of millions of pounds for charity alongside leading royals and is also an avid art collector, with work by Scottish artist Jack Vettriano among the items he owns.

Braveheart Investment Group PLC (LON:BRH) said one of its strategic investments, Gyrometric Systems, received a cash injection of �250,000 on Tuesday from Strat Aero PLC. As a result of the fund-raising, Strat Aero now holds a 37% stake in Gyrometric while Braveheart�s stake has been reduced to 41% as a result of the issue of new shares. The paper-based net uplift in the value of Braveheart's holding, after accounting for profit shares due to third parties and subject to audit, is expected to be in the region of �100,000. READ Strat Aero invests �0.25mln in rotating shaft monitoring company​ "Braveheart has worked closely with Gyrometric to drive its business forward over the last year,� said Braveheart director, Viv Hallam. �This investment confirms the value of our work and our belief in this market opportunity, it brings access to further resources and skills to this business. We welcome the investment by Strat Aero plc and look forward working with Nigel Burton, who is joining the Gyrometric board with immediate effect,� Hallam added.

Welcome to Small-Cap Spotlight where the Evening Standard business team will bring investors rolling coverage and analysis on all the major small cap news this morning. Top story sees Michael Spencer - who is in the process of completing a multi-billion deal for NEX - up his stake in Cluff Natural Resources.